Targeting PI3Kδ: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting PI3Kδ: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond
Authors
Keywords
-
Journal
MEDICINAL RESEARCH REVIEWS
Volume 35, Issue 4, Pages 720-752
Publisher
Wiley
Online
2015-03-11
DOI
10.1002/med.21341
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia
- (2015) Xiang Wang et al. Oncotarget
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies
- (2014) Elisa ten Hacken et al. PHARMACOLOGY & THERAPEUTICS
- PI3-Kinase Inhibitors in Chronic Lymphocytic Leukemia
- (2014) Julie E. Chang et al. Current Hematologic Malignancy Reports
- A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth
- (2013) Xiang Wang et al. ACTA PHARMACOLOGICA SINICA
- Identification of GNE-293, a potent and selective PI3Kδ inhibitor: Navigating in vitro genotoxicity while improving potency and selectivity
- (2013) Brian S. Safina et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Targeted Therapy in Chronic Lymphocytic Leukemia: Past, Present, and Future
- (2013) Alexey V. Danilov CLINICAL THERAPEUTICS
- Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729
- (2013) Peter Norman EXPERT OPINION ON THERAPEUTIC PATENTS
- Improving the Treatment Outcome of Patients with Chronic Lymphocytic Leukemia Through Targeted Antibody Therapy
- (2013) Deborah M. Stephens et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity
- (2013) Chudi O. Ndubaku et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of PI3K inhibitors: lessons learned from early clinical trials
- (2013) Jordi Rodon et al. Nature Reviews Clinical Oncology
- IPI-145 Shows Promise in CLL Patients
- (2013) Cancer Discovery
- Potent and selective inhibitors of PI3Kδ: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf
- (2012) Daniel P. Sutherlin et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia
- (2012) S. E. M. Herman et al. CLINICAL CANCER RESEARCH
- Evaluation of WO2012032067 and WO2012055846: two selective PI3Kδ inhibitors, which is GSK-2269557?
- (2012) Peter Norman EXPERT OPINION ON THERAPEUTIC PATENTS
- Discovery and in Vivo Evaluation of Dual PI3Kβ/δ Inhibitors
- (2012) Felix Gonzalez-Lopez de Turiso et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Novel PI3-Kinase δ Specific Inhibitors for the Treatment of Rheumatoid Arthritis: Taming CYP3A4 Time-Dependent Inhibition
- (2012) Brian S. Safina et al. JOURNAL OF MEDICINAL CHEMISTRY
- Potent and Highly Selective Benzimidazole Inhibitors of PI3-Kinase Delta
- (2012) Jeremy M. Murray et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- B-cell receptor signaling in chronic lymphocytic leukemia
- (2011) F. K. Stevenson et al. BLOOD
- Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
- (2011) A Smith et al. BRITISH JOURNAL OF CANCER
- Present and Future of PI3K Pathway Inhibition in Cancer: Perspectives and Limitations
- (2011) E. Ciraolo et al. CURRENT MEDICINAL CHEMISTRY
- Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer
- (2011) Daniel P. Sutherlin et al. JOURNAL OF MEDICINAL CHEMISTRY
- IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells
- (2011) M Coscia et al. LEUKEMIA
- The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
- (2011) Jatin Roper et al. PLoS One
- Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
- (2011) Matthew T. Burger et al. ACS Medicinal Chemistry Letters
- PI3K Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic
- (2011) D. A. Fruman et al. Cancer Discovery
- Identification and structure–activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors
- (2010) Sabina Pecchi et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
- (2010) P. Workman et al. CANCER RESEARCH
- Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
- (2010) Bruce D. Cheson JOURNAL OF CLINICAL ONCOLOGY
- Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer
- (2010) Daniel P. Sutherlin et al. JOURNAL OF MEDICINAL CHEMISTRY
- The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors
- (2010) Alex Berndt et al. Nature Chemical Biology
- The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia
- (2010) Graham Packham et al. SEMINARS IN CANCER BIOLOGY
- First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
- (2010) Carmen Schweighofer OncoTargets and Therapy
- Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors
- (2010) Matthew T. Burger et al. ACS Medicinal Chemistry Letters
- Effect of ZSTK474, a Novel Phosphatidylinositol 3-Kinase Inhibitor, on DNA-Dependent Protein Kinase
- (2009) Dexin Kong et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors
- (2009) Dexin Kong et al. CURRENT MEDICINAL CHEMISTRY
- Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ
- (2009) Michael Ameriks et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden
- (2009) S. Y. Kristinsson et al. HAEMATOLOGICA
- Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
- (2009) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia
- (2009) Wolfgang U. Knauf et al. JOURNAL OF CLINICAL ONCOLOGY
- Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
- (2009) F. I. Raynaud et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Regulation of phosphoinositide 3-kinase expression in health and disease
- (2009) Klaartje Kok et al. TRENDS IN BIOCHEMICAL SCIENCES
- Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway
- (2008) Frédéric Stauffer et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
- (2008) C. S. Tam et al. BLOOD
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now